South Africa to Produce Groundbreaking HIV Prevention Drug

A breakthrough HIV prevention drug that works with just two shots a year is coming to South Africa through a new manufacturing deal that could change millions of lives.

The South African government is finalizing an agreement with Gilead Sciences to produce lenacapavir domestically. This matters because South Africa has one of the world's highest HIV burdens, and local production typically means lower costs and better access.

The drug itself is remarkable. Clinical trials showed that lenacapavir injections every six months provide virtually complete protection against HIV infection. That's a game changer compared to daily pills that many people struggle to take consistently.

Right now, South Africa is working with Unitaid and the US Pharmacopeia to identify local companies capable of manufacturing the medicine to international standards. The process ensures that locally produced versions will be just as effective as the original.

The timing is crucial. Health providers and policymakers have been pushing for broader access to lenacapavir since the stunning trial results emerged. A voluntary license from Gilead means South African manufacturers won't face patent barriers that typically keep drug prices high.

This approach has worked before. South Africa successfully produces generic versions of other HIV medications, making treatment affordable for millions of people who need it. The same model could now extend to prevention.

The Ripple Effect

This deal represents more than just one country getting access to one drug. It's a model for how pharmaceutical companies and governments can work together to get life-saving medicines to the people who need them most.

When South Africa builds capacity to manufacture lenacapavir, neighboring countries could benefit too. Regional production hubs often supply medicines across entire continents, multiplying the impact far beyond one nation's borders.

The arrangement also sends a signal to other drugmakers. Voluntary licensing can be good business while also serving public health, especially when it opens up markets that might otherwise remain out of reach.

For people at high risk of HIV infection, the promise is simple but profound: protection that doesn't require daily decisions or perfect adherence. Just two visits to a clinic each year could mean the difference between infection and staying healthy.

South Africa's decades of experience manufacturing HIV treatments means they have the expertise to do this well, and do it quickly.